Intus Biosciences
Farmington, US · Founded 2014 · Connecticut LLC · 1 known investors
Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.
Founders & leadership
Intus Biosciences was founded in 2014 by Thomas P Jarvie, Mark D. Driscoll, and Mark Driscoll.
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.1M disclosed across 10 rounds · 2016–2025
▶$1.1MraisedMay 2025 · 8 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMay 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Donna GalluzzoDirector
- Paul DenslowExecutive Officer, Director
- Frank J. MarcoDirector
- Alan MendelsonDirector
- Daniel WagnerDirector
- Mark DriscollDirector
- Offering amount
- $3M
- Amount sold
- $1.1M
- First sale
- May 2025
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$2MraisedJul 2024 · 25 investors · BiotechnologyRule 506(b)
▶$2MraisedJul 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul DenslowExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jun 2024
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.1MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$1.1MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas JarvieExecutive Officer, Director
- Paul DenslowExecutive Officer, Director
- Alan MendelsonDirector
- Matt WatsonDirector
- Frank J. MarcoDirector
- Offering amount
- $3.5M
- Amount sold
- $1.1M
- First sale
- Nov 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$800KraisedJul 2022 · 1 investors · BiotechnologyRule 506(b)
▶$800KraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William McKenzieDirector
- H. Mark LunenburgDirector
- David WurzerDirector
- Paul DenslowExecutive Officer, Director
- Alan MendelsonDirector
- Thomas JarvieExecutive Officer, Director
- Frank J. MarcoDirector
- Offering amount
- $1.5M
- Amount sold
- $800K
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$250KraisedFeb 2022 · 4 investors · BiotechnologyRule 506(b)
▶$250KraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William McKenzieDirector
- H. Mark LunenburgDirector
- David WurzerDirector
- Thomas JarvieExecutive Officer, Director
- Paul DenslowDirector
- Frank MarcoDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Jan 2022
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$330KraisedJan 2021 · 5 investors · BiotechnologyRule 506(b)
▶$330KraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas JarvieExecutive Officer, Director
- William McKenzieDirector
- Frank MarcoDirector
- Patrick O'NeillDirector
- H. Mark LunenburgDirector
- Offering amount
- $1M
- Amount sold
- $330K
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$2.2MraisedMay 2020 · 16 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas JarvieExecutive Officer, Director
- William McKenzieDirector
- Patrick O'NeillDirector
- Frank MarcoDirector
- H. Mark LunenburgDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- May 2019
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
▶$1.8MraisedDec 2017 · 10 investors · BiotechnologyRule 506(b)
▶$1.8MraisedDec 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank J. MarcoDirector
- Mark D. DriscollExecutive Officer, Director
- Patrick O'NeillDirector
- Thomas P. JarvieExecutive Officer, Director
- Offering amount
- $1.9M
- Amount sold
- $1.8M
- First sale
- Dec 2017
- Incorporated
- Limited Liability Company, Connecticut, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapHurdle4 shared keywordsHurdle provides a modular diagnostic infrastructure platform with APIs and low/no-code tools for ordering diagnostics, integrating results with EHRs, and coordinating sample collection. It serves clinics, digital health providers, diagnostics companies, and research institutions, and offers an AI-driven multi-omics platform for biomarker discovery and precision medicine.
Tiny Health4 shared keywordsTiny Health offers at-home gut and vaginal microbiome test kits with age-specific, evidence-based reports that recommend diet, supplement, and lifestyle changes. It targets families across life stages—from preconception and pregnancy through infancy, childhood, and adulthood—to detect microbiome imbalances and support prevention of conditions like eczema, allergies, and GI issues.
Rupa Health4 shared keywordsA platform that enables healthcare providers to order, track, and receive lab test results from multiple laboratory companies through a single dashboard, supporting both in-person and telehealth patients with flexible billing options and EHR integration.
Pacb4 shared keywordsPacBio develops long-read DNA sequencing systems and kits, including its Revio and Sequel II platforms and HiFi/SMRT sequencing technology, for whole genome, targeted, epigenetic, and RNA sequencing. Its products serve genomics researchers and clinical and diagnostic research labs studying humans, plants, animals, and microbes.
Viome4 shared keywordsViome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.
BIOHM3 shared keywordsBIOHM sells probiotic supplements and at-home gut test kits that analyze the microbiome, with results reviewed by a microbiome-trained registered nutritionist who provides personalized diet and supplement recommendations. Its formula combines bacteria, fungi, and a digestive enzyme intended to support digestive health.
Companies competing with Intus Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Intus Biosciences do?
- Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.
- Who founded Intus Biosciences?
- Intus Biosciences was founded by Thomas P Jarvie, Mark D. Driscoll, Mark Driscoll in 2014.
- Who are Intus Biosciences's investors?
- Intus Biosciences's investors include Connecticut Innovations.
- How much funding has Intus Biosciences raised?
- Intus Biosciences has disclosed $10.1M raised across 10 rounds.
- Where is Intus Biosciences headquartered?
- Intus Biosciences is headquartered in Farmington, US.